A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined with JNJ 78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer
Study of JNJ-87189401 in Combination with JNJ 78278343 in Patients with Prostate Cancer
Sponsor: Janssen Research & Development, LLC
Enrolling: Male and Female Patients
IRB Number: AAAU8797
U.S. Govt. ID: NCT06095089
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out the side effects of JNJ-87189401 given in combination with JNJ-78278343 to patients with metastatic castration-resistant prostate cancer, and to find which doses of the two study drugs when given in combination cause the least side effects. The study will also look at how long JNJ-87189401 and JNJ-78278343 stay in the body, how they act on the body, and how the body responds to them. JNJ-87189401 and JNJ-78278343 have not been approved by the Food and Drug Administration (FDA). This is the first time that JNJ-87189401 will be used in people. JNJ-78278343 has been given to about 90 people with prostate cancer in a different study. It has never been used in combination with JNJ-87189401. This is the first time that the combination will be given to people.
Mark Stein, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you had a solid organ or bone marrow transplant? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator